RX News

MISSISSAUGA, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 800,000 of its common shares (“Shares”) over a 12-month period, representing approximately 7.1% of the Shares outstanding as of December 15, 2025.

MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and six months ended June 30, 2025 on Thursday, August 21, 2025 after market hours. A presentation on the Company’s second quarter and first half 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.